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Abstract: BACKGROUND Remote monitoring (RM) technology embedded in cardiac rhythm devices
permits continuous monitoring of device function, and recording of selected cardiac physiological param-
eters and cardiac arrhythmias and may be of utmost utility during Coronavirus (COVID-19) pandemic,
when in-person office visit for regular follow-up were postponed. However, patients not alredy followed-
up via RM represent a challenging group of patients to be managed during the lockdown. METHODS
We reviewed patient files scheduled for an outpatient visit between January 1, 2020 and May 11th, 2020
to assess the proportion of patients in whom RM activation was possible without office visit, and com-
pared them to those scheduled for visit before the lockdown. RESULTS During COVID-19 pandemic,
RM activation was feasible in a minority of patients (7.8% of patients) expected at outpatient clinic for
a follow-up visit and device check-up. This was possible in a good proportion of complex implantable
devices such as cardiac resynchronization therapy and implantable cardioverter defibrillator but only in
3 patients with a pacemaker the RM function could be activated during the period of restricted access to
hospital. CONCLUSIONS Our experience strongly suggest to consider the systematic activation of RM
function at the time of implantation or - by default programming - in all cardiac rhythm management
devices.
DOI: https://doi.org/10.1016/j.ijcard.2020.11.063
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Background: Remote monitoring (RM) technology embedded in cardiac rhythm devices permits continuous
monitoring of device function, and recording of selected cardiac physiological parameters and cardiac arrhyth-
mias andmay be of utmost utility during Coronavirus (COVID-19) pandemic, when in-person office visit for reg-
ular follow-up were postponed. However, patients not alredy followed-up via RM represent a challenging group
of patients to be managed during the lockdown.
Methods: We reviewed patient files scheduled for an outpatient visit between January 1, 2020 and May 11th,
2020 to assess the proportion of patients inwhom RM activation was possiblewithout office visit, and compared
them to those scheduled for visit before the lockdown.
Results: During COVID-19 pandemic, RM activation was feasible in a minority of patients (7.8% of patients) ex-
pected at outpatient clinic for a follow-up visit and device check-up. This was possible in a good proportion of
complex implantable devices such as cardiac resynchronization therapy and implantable cardioverter defibrilla-
tor but only in a minority of patients with a pacemaker the RM function could be activated during the period of
restricted access to hospital.
Conclusions: Our experience strongly suggest to consider the systematic activation of RM function at the time of
implantation or – by default programming - in all cardiac rhythm management devices.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Background
Remote monitoring (RM) technology embedded in cardiac
rhythm devices permits continuous monitoring of device function, and
recording of selected cardiac physiological parameters and cardiac
arrhythmias. RM is associated with improved survival, and a graded re-
lationship with the level of adherence [1]. During Coronavirus (COVID-
19) pandemic [2], in-person office visit for regular follow-upwere post-
poned and scientific societies called for massive implementation of RM
in cardiac rhythmdevice patients [3,4]. However, patients not followed-
up via RM represent a challenging group of patients to be managed. RM
activation usually requires programming steps during in-office visit,
registering transmitter and obtaining consent from the patients. This
leaves aged patients at risk of infection in case they are seen in the
hospital or at outpatient clinic [5,6], and can be time consuming in
these unprecedented times of limited resource availability. On the
other hand, RM initialization without the patients coming to the office
or hospital is technically feasible but the RM function needs to be al-
ready activated. When the device RM function is turned ON, the patient
only needs to plug in the transmitter device and follows few steps for
initiating transmission. In selected device types (Boston Scientific, Ab-
bott, Microport and Medtronic Pacemakers, Medtronic devices using
BlueSync technology and last generation Microport ICD/CRT) (Fig. 1),
RM is programmed by default ON thus, easily enabling activation with-
out significant interaction by hospital personnel and patient. For other
devices manufacturers (Biotronik and previous generation of Microport
andMedtronic ICD or CRT), remote monitoring needs an in-person visit
with the need of programming ON the device, although this function
may be turned ON at the time of implant. This is not clearly recom-
mended by international scientific societies [7,8]; thus, it is not custom-
ary in the vast majority of hospitals including ours especially for
patients with pacemakers. We aimed to report the proportion of
patients in whom RM was possible without office visit during the
COVID-19 pandemic.
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2. Methods
We reviewed patient files scheduled for an outpatient visit between
January 1, 2020 andMay 11th, 2020 to assess the proportion of patients
inwhomRMactivationwas possiblewithout office visit. RM technology
became available at our Institution in 2010. Before the pandemic period,
for institution's policy, most of devices on RMwere ICD and CRT-D; only
a minority of devices (4%) were PMs, due to the lack of reimbursement
and of large scientific evidence. We compared the group of patients be-
fore local authorities (Canton Ticino, Switzerland) restricted access to
hospital and offices (March 18th, 2020) to those during the period of re-
stricted access which ended on May 11th, 2020 in Canton Ticino, one of
Swiss Cantons, in which RM of all implanted device (3 implanting cen-
ters) is exclusively managed by one institution (Cardiocentro Ticino),
thus working as RM device hub. As indicated by scientific societies [9]
patientswith ICD/CRT-D have a scheduled in office visit every 6months,
and patientswith PM are scheduled every year. During the pandemic, in
patients with RM, we scheduled a transmission per month in patients
with CRT-D/ICD and a transmission every two months in patients
with IPG.
3. Results
A total of 550 patients were scheduled for in-person visit during the
first 19 weeks of year 2020. The weekly and total number of patients
expected at follow-up before and during the pandemic hospital out-
patient clinic closure were similar (Table 1) During COVID-19 pan-
demic, RM activation was feasible in a minority of patients (7.8% of pa-
tients) expected at outpatient clinic for a follow-up visit and device
check-up; this was possible in a good proportion of complex implant-
able devices such as cardiac resynchronization therapy and implantable
cardioverter defibrillator of some device manufacturers (Boston Scien-
tific, and Microport) by sending the external device directly to the pa-
tients. Only in 3 patients with a pacemaker (Fig. 1) the RM function
could be activated during the period of restricted access to hospital. In
a few cases of device by Medtronic (2 patients) and Biotronik (2
patients), it was possible to active RM because they the RM function
was already activated at implantation time (Fig. 1). A total of 15 patients
without RM complained symptoms during the COVID pandemic (3 syn-
cope; 11palpitations; 1 dizziness), 2 patients reported an acoustic alarm
and 2 patients experienced ICD interventions requiring hospital admis-
sion. These cases could have been managed by RM to rule out arrhyth-
mias or devices malfunction.
4. Discussion
Our experience strongly suggest to consider the systematic activa-
tion of RM function at the time of implantation or – by default program-
ming - in all cardiac rhythm management devices. This shall allow an
easy activation of RM function without major physical interaction
with hospital nurse or technician especially when access to outpatient
clinic is critically restricted as during pandemic and/or there is a
Fig. 1. Panel A shows the proportion of patients with RMbefore and during COVID-19 pandemic according to cardiac implantable electronic device type. Panel B and C show distribution of
device manufacturers before and during COVID-19 pandemic. The asterisk indicates the proportion of patients in whom RM activation without in-person visit was feasible.
Table 1









Mar 19, 2020 - May
11, 2020
(n = 271)
Age – yr 72 73
Male sex – no (%) 212 (75.8%) 206 (76.0%)
Coronary artery disease – no. (%) 135 (48%) 141 (52%)
Atrial fibrillation – no. (%) 89 (32%) 97 (36%)
Cardiac Implantable Electronic Device
type – no. (%)
- Implantable
cardioverter-defibrillator
55 (20%) 36 (14%)
- Cardiac resynchronization therapy 60 (21%) 61 (23%)
- Implantable pulse generator 165 (59%) 174 (64%)
Remote monitoring refused by
patient – no. (%)
3 (1.1%) 2 (0.7%)
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shortage in human resources. Cardiac rhythm device patients may be
considered at particular risk of COVID-19 infection because of their av-
erage age (60 to 80 years old), the cardiovascular risk profile and the
significant burden of co-morbidities such as atrial fibrillation, diabetes,
peripheral vascular artery disease, chronic obstructive pulmonary dis-
ease, etc. Although the replacement of in-person visit by a massive
adoption of RM has been advocated by international scientific societies,
the implementation has been challenging due to technical limitations
experienced in providing the patientswith hardware required for trans-
mission. At the time of pandemic breakout only 3 out of 5 device man-
ufacturers enables RM activation without the patients coming to the
office or hospital. On the other hand, several pacemaker patients in
whom RM activation was technical feasible were very reluctant in
being remotely monitored. This situation contrasted the acceptance of
RM by patients with more complex devices in whom RMwas easily ac-
tive in a large proportion of patients. The precise reason for the differ-
ence is unknown but may be due to patient's age or perceived benefit
by the patients and caregivers of the value of RM in pacemaker patients.
Alternatively as shown by Varma et al. [1], the degree of RM use in USA
showed wide geographic variability especially in rural area or in areas
with challenging socio-economic conditions. In conclusions, recom-
mendation by international scientific societies about systematic RM ac-
tivation function in all cardiac rhythm device patients at the time of
implantation shall be explicitly formulated. Furthermore possible
amendment of the restriction imposed by General Data Protection Reg-
ulation, which prohibits the direct shipment of transmitter to the
patient's home by manufacturers shall be considered. Finally, one of
the most important reported barriers to the implementation of RM is
the lack of reimbursement and the increased institutional workload
[10]. Therefore, further efforts to improve RM drivers (reimbursement,
patient's awareness of a need for RM and related benefits, and avoid-
ance of in-office follow-ups during a pandemic) are stronglywarranted.
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